Biagio Ricciuti: Vulnerabilities to GPX4 and HDAC inhibitors in BRAF V600E lung adenocarcinoma
Biagio Ricciuti posted on X about recent paper by Marie-Julie Nokin et al., titled “In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF lung adenocarcinoma” published on Science Direct.
Authors: Marie-Julie Nokin, Elodie Darbo, Elodie Richard, Sonia San José, Sergio de Hita, Valérie Prouzet-Mauleon, Béatrice Turcq, Laura Gerardelli, Rebekah Crake, Valérie Velasco, Benjamin Koopmansch, Frederic Lambert, Jenny Y. Xue, Ben Sang, Julie Horne, Eric Ziemons, Alberto Villanueva, Arnaud Blomme, Michael Herfs, Didier Cataldo, David Santamaría.
“Our collaborative effort uncovering in vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent vs. drug-resistant BRAF V600E lung adenocarcinoma is out in Cell Reports Medicine!
With Santamaria Lab and Ambrogio Lab.”
Source: Biagio Ricciuti/X
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.